Cholesterol Absorption Inhibitors and PCSK9 Inhibitors

Introduction/Overview

Elevated low‑density lipoprotein cholesterol (LDL‑C) remains a principal modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). In recent decades, therapeutic advances have focused on both reducing hepatic LDL‑C production and enhancing its clearance from circulation. Cholesterol absorption inhibitors and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent two distinct strategies that have expanded the therapeutic armamentarium for dyslipidemia. These agents exhibit complementary pharmacological profiles, allowing them to be employed individually or in combination with statins and other lipid‑lowering therapies to achieve target LDL‑C levels, particularly in patients with familial hypercholesterolemia (FH) or statin intolerance.

Clinical relevance is underscored by the growing evidence that more aggressive LDL‑C lowering translates into reduced ASCVD events. Moreover, as statin‑based regimens reach their maximal tolerated doses or are contraindicated, non‑statin therapies become indispensable. Understanding the mechanism, pharmacokinetics, therapeutic indications, and safety profile of cholesterol absorption inhibitors and PCSK9 inhibitors is therefore essential for clinicians prescribing lipid‑lowering therapy.

Learning objectives

• Describe the pharmacological classification and chemical nature of cholesterol absorption inhibitors and PCSK9 inhibitors.
• Explain the mechanisms of action at the molecular and cellular levels for both drug classes.
• Summarize the pharmacokinetic parameters, dosing regimens, and therapeutic indications for each agent.
• Identify common adverse effects, potential drug interactions, and special considerations related to pregnancy, lactation, pediatrics, geriatrics, and organ dysfunction.
• Apply knowledge to formulate evidence‑based lipid‑lowering strategies, including combination therapy and patient selection.

Classification

Cholesterol Absorption Inhibitors

Cholesterol absorption inhibitors constitute a small class of orally administered agents that block intestinal cholesterol uptake. The most widely studied and approved member of this class is ezetimibe, a 2‑(2‑nitro‑4‑(trifluoromethyl)phenyl)-1‑(1,3‑bis‑(4‑fluorophenyl)–2,4‑dioxo­pyrrolo[3,4‑c]pyrimidin‑3‑yl)‑3‑(1‑methyl‑4‑thiazolyl)‑1‑(1‑(2‑(1,3,7‑trioxaborolyl)‑1‑(1,3,5‑trioxobenzyl)di­methylcarbinyl)‑1‑(2‑(1,3,5‑trioxobenzyl)‑1‑(1,3,7‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑2‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)‑1‑(1,3,5‑trioxobenzyl)

No other cholesterol absorption inhibitors have received regulatory approval for clinical use to date; however, investigational compounds targeting the Niemann‑Pick C1‑like 1 (NPC1L1) transporter are under development.

PCSK9 Inhibitors

PCSK9 inhibitors are biologic agents that reduce circulating PCSK9 levels or impede its interaction with low‑density lipoprotein receptors (LDLR). Two monoclonal antibodies (alirocumab and evolocumab) and one small interfering RNA (inclisiran) are approved in most jurisdictions.

From a chemical standpoint, monoclonal antibodies are large glycoproteins (~150 kDa) composed of two heavy and two light chains linked by disulfide bonds. Inclisiran is a 21‑mer double‑stranded RNA conjugated to a tri‑antennary tri‑galactose ligand that facilitates hepatocyte uptake via asialoglycoprotein receptors.

Beyond the approved agents, other PCSK9‑targeting molecules—such as antibody fragments, nanobodies, and small‑molecule inhibitors—are under clinical investigation and represent an expanding category within lipid‑lowering therapies.

Mechanism of Action

Cholesterol Absorption Inhibitors

Intestinal cholesterol absorption is mediated primarily by the NPC1L1 transporter, situated on the brush border membrane of enterocytes. Ezetimibe binds selectively to NPC1L1, inhibiting the uptake of dietary and biliary cholesterol. As a consequence, the intestinal lumen retains a larger fraction of cholesterol, which is subsequently excreted in feces. The net effect is a reduction in the cholesterol pool available for hepatic synthesis and VLDL secretion, yielding a modest decrease in LDL‑C (typically 15–20%).

In vitro studies indicate that ezetimibe does not alter the expression of NPC1L1; instead, it stabilizes the transporter in an inactive conformation. The blockade is reversible and occurs at the intestinal level, sparing hepatic CYP enzymes and thereby minimizing drug‑drug interactions that are characteristic of statin therapy.

PCSK9 Inhibitors

PCSK9 is a serine protease secreted primarily by hepatocytes. It binds to the extracellular domain of LDLR on the hepatocyte surface, promoting ubiquitination and lysosomal degradation of the receptor. Consequently, fewer LDLR molecules are recycled to the cell membrane, resulting in reduced clearance of LDL‑C from plasma.

Monoclonal antibody therapy (alirocumab, evolocumab) exerts its effect by neutralizing circulating PCSK9, thereby preventing its interaction with LDLR. The antibodies are engineered to bind with high affinity to the catalytic domain of PCSK9, blocking receptor binding sites. By sequestering PCSK9, the antibodies restore LDLR recycling and enhance LDL‑C uptake.

Inclisiran operates via an RNA interference (RNAi) mechanism. After endocytosis by hepatocytes, its sense strand is incorporated into the RNA-induced silencing complex (RISC). The antisense strand guides RISC to PCSK9 messenger RNA (mRNA), resulting in its cleavage and degradation. The net outcome is a sustained reduction in PCSK9 protein synthesis, leading to increased LDLR availability. Inclisiran’s liver‑specific delivery confers prolonged pharmacodynamic effects, allowing dosing intervals of approximately six months.

In both antibody and RNA‑based modalities, the effect is specific to PCSK9, thereby sparing other pathways involved in cholesterol metabolism. This selectivity contributes to a favorable safety profile relative to agents targeting upstream enzymes such as HMG‑CoA reductase.

Pharmacokinetics

Ezetimibe

Absorption of ezetimibe occurs primarily in the proximal small intestine. Peak plasma concentrations (Tmax) are reached within 2–4 hours after oral dosing. The drug exhibits a low absolute bioavailability (~5–6%) due to extensive first‑pass metabolism, largely mediated by CYP3A4 and CYP2C9 in the liver and intestinal wall. Approximately 80% of ezetimibe is bound to plasma proteins, predominantly albumin and alpha‑1‑acid glycoprotein.

Metabolism yields several inactive metabolites, primarily through glucuronidation and sulfation. Renal excretion accounts for ~20% of the total clearance; the remainder is eliminated via biliary excretion of metabolites. The terminal half‑life of ezetimibe is approximately 22 hours, permitting once‑daily dosing. Due to its extensive hepatic metabolism, dose adjustment is not routinely required in mild to moderate hepatic impairment, while severe hepatic dysfunction may necessitate careful monitoring.

Alirocumab

Alirocumab is administered subcutaneously, with peak serum concentrations occurring 48–72 hours post‑injection. The drug is highly protein‑bound (>99%) and exhibits a volume of distribution consistent with a peripheral compartment. Metabolism proceeds via proteolytic catabolism and protease‑mediated degradation, akin to other IgG1 monoclonal antibodies. Renal and hepatic impairment do not significantly influence clearance, owing to the protein‑based elimination pathways. The terminal half‑life ranges from 11 to 13 days, supporting dosing intervals of 2 to 4 weeks depending on the prescribed regimen (e.g., 140 mg every 2 weeks or 420 mg monthly).

Evolocumab

Similar pharmacokinetic features are observed for evolocumab. Subcutaneous administration results in a Tmax of 48–72 hours. The drug is >99% protein‑bound, and its clearance follows linear kinetics across a broad dose range. The terminal half‑life approximates 17 days, enabling dosing every 2 weeks or monthly. Renal or hepatic dysfunction does not necessitate dose modification, although post‑marketing surveillance continues to monitor for rare adverse events.

Inclisiran

Inclisiran is delivered via subcutaneous injection, typically at 300 mg for the initial dose, followed by a second dose at 3 months. The drug undergoes rapid hepatic uptake mediated by asialoglycoprotein receptors. Within hepatocytes, the RNA duplex is incorporated into RISC, leading to sustained PCSK9 mRNA degradation. Pharmacokinetic studies reveal a terminal half‑life of ~90 days, which underpins the biannual dosing schedule. Because inclisiran is largely confined to the liver, systemic exposure is limited, and renal or hepatic impairment does not significantly alter its pharmacokinetic profile.

Therapeutic Uses/Clinical Applications

Cholesterol Absorption Inhibitors

Approved indications for ezetimibe include:

• Adjunctive therapy to statins for patients with hypercholesterolemia who fail to reach LDL‑C goals.
• Monotherapy for patients intolerant to statins or with contraindications to statin use.
• Management of homozygous familial hypercholesterolemia (HoFH) when combined with bile acid sequestrants or PCSK9 inhibitors.

In real‑world practice, ezetimibe is frequently combined with statins to achieve additive LDL‑C reduction. The combination is well tolerated and does not appear to increase the incidence of myopathy beyond that seen with statins alone. Evidence suggests that the addition of ezetimibe can reduce LDL‑C by an additional 15–20% in statin‑treated patients, thereby improving ASCVD risk profiles.

PCSK9 Inhibitors

Indications for PCSK9 inhibitors encompass:

• Heterozygous familial hypercholesterolemia (HeFH) when LDL‑C targets remain unmet with maximally tolerated statin therapy.
• Patients with ASCVD requiring LDL‑C reduction below 1.4 mmol/L (55 mg/dL) despite statin therapy.
• Statin‑intolerant patients with elevated LDL‑C who cannot tolerate or are contraindicated for statins.
• Patients with HoFH, often in combination with bile acid sequestrants, statins, or lomitapide.
• Secondary prevention in individuals with high residual cardiovascular risk after acute coronary syndrome or stroke.

Clinical trials demonstrate that monoclonal antibodies can reduce LDL‑C by 50–60%, while inclisiran achieves reductions of 40–45% when combined with statins. These lipid‑lowering effects translate into substantial reductions in major cardiovascular events, as shown in large randomized controlled trials (e.g., FOURIER for evolocumab, ODYSSEY for alirocumab, and ORION‑10/11 for inclisiran).

Adverse Effects

Ezetimibe

Common adverse events include gastrointestinal symptoms such as abdominal pain, diarrhea, and nausea. Headache and arthralgia may occur but are infrequent. Serious adverse reactions are rare; no black‑box warnings have been issued. Rarely, hypersensitivity reactions (rash, pruritus) have been reported. Because ezetimibe is not metabolized by CYP450 enzymes, drug‑drug interactions are limited, but caution is advised when co‑administered with agents that alter intestinal motility.

PCSK9 Inhibitors

Monoclonal antibodies are generally well tolerated. The most common adverse events are injection‑site reactions (erythema, pruritus, induration) and mild flu‑like symptoms (fever, myalgia). Serious hypersensitivity or anaphylactic reactions are exceedingly uncommon. No black‑box warnings exist, although post‑marketing surveillance continues to monitor for rare events such as new‑onset diabetes or neurocognitive adverse events, although evidence remains inconclusive.

Inclisiran’s adverse event profile mirrors that of the antibody class, with injection‑site reactions being most frequent. Because inclisiran’s hepatic uptake is highly specific, systemic side effects are minimal. Long‑term safety data from the ORION trials indicate that the incidence of serious adverse events is comparable to placebo. No black‑box warnings are currently in effect.

Drug Interactions

Ezetimibe

Ezetimibe has minimal interaction potential due to its limited metabolism via CYP3A4 and CYP2C9. However, strong inhibitors or inducers of these enzymes can alter ezetimibe exposure. Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole) may increase ezetimibe plasma concentrations, potentially elevating the risk of adverse effects. Similarly, CYP3A4 inducers (e.g., rifampin) may decrease ezetimibe levels, reducing efficacy. Co‑administration with statins is generally considered safe, and the combination has not been shown to increase the incidence of myopathy beyond that associated with statin monotherapy.

PCSK9 Inhibitors

Due to their large molecular size and non‑enzymatic mechanism, PCSK9 inhibitors exhibit negligible pharmacokinetic interactions. The primary concern lies in potential immunogenicity or anti‑drug antibody formation, which could reduce efficacy. No clinically significant drug‑drug interactions have been documented for monoclonal antibodies or inclisiran. Nonetheless, concomitant use with other biologic agents may theoretically increase the risk of immune‑mediated adverse events, warranting clinical vigilance.

Special Considerations

Pregnancy and Lactation

Data in pregnancy are limited; animal studies indicate that PCSK9 inhibitors cross the placenta, but human studies are sparse. Consequently, use during pregnancy is generally discouraged unless the potential benefit outweighs the unknown risk. Similar caution applies to lactation; no evidence suggests that ezetimibe or PCSK9 inhibitors are secreted in breast milk in clinically significant amounts, yet data are insufficient to endorse routine use in nursing mothers.

Pediatric Considerations

In children with HeFH or HoFH, statin therapy is often initiated early. Ezetimibe has been approved for use in pediatric patients aged 10 years and older, with dosing based on weight. PCSK9 inhibitors have been studied in adolescents with FH (age ≥ 12 years) and have shown favorable lipid‑lowering effects. Long‑term safety data in this population remain limited; ongoing registries aim to capture outcomes related to growth, neurocognitive development, and immune response.

Geriatric Considerations

Older adults frequently present with polypharmacy and comorbidities. Because ezetimibe is not heavily metabolized by hepatic enzymes, it may be preferable in frail patients with hepatic impairment. PCSK9 inhibitors’ lack of significant drug interactions makes them attractive for geriatric patients. However, injection‑site reactions may be more noticeable in this demographic, and adherence to biweekly or biannual dosing schedules should be encouraged.

Renal and Hepatic Impairment

Renal impairment does not necessitate dose adjustments for ezetimibe, PCSK9 antibodies, or inclisiran, as clearance is primarily hepatic or via proteolytic catabolism. Hepatic impairment may modestly increase ezetimibe exposure, but no formal dose reduction is required for mild or moderate dysfunction. In severe hepatic disease, caution is advised, and therapy should be individualized based on risk‑benefit assessment. For inclisiran, no dose modification is recommended for patients with chronic kidney disease (CKD) stages 1–4, and data for stage 5 remain limited.

Summary/Key Points

• Ezetimibe reduces cholesterol absorption by inhibiting NPC1L1, yielding modest LDL‑C lowering and minimal drug‑drug interactions.
• PCSK9 inhibitors (alirocumab, evolocumab, inclisiran) enhance LDL‑C clearance by neutralizing or silencing PCSK9, achieving 40–60% LDL‑C reduction.
• Both drug classes are generally well tolerated; injection‑site reactions are the most common adverse event for PCSK9 inhibitors.
• Therapeutic indications span heterozygous and homozygous FH, ASCVD risk reduction, and statin intolerance.
• Special populations—pregnancy, lactation, pediatrics, geriatrics, and organ dysfunction—require individualized assessment, though no major dosing alterations are typically necessary for mild to moderate hepatic or renal impairment.
• Combination therapy with statins offers additive LDL‑C reduction without significant increase in adverse events, supporting a stepwise approach to lipid management.

References

1. Rowland M, Tozer TN. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications. 4th ed. Philadelphia: Wolters Kluwer; 2011.
2. Shargel L, Yu ABC. Applied Biopharmaceutics & Pharmacokinetics. 7th ed. New York: McGraw-Hill Education; 2016.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
5. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.